Esperion Therapeutics Inc., (Nasdaq: ESPR), the pharmaceutical company developing promising new cholesterol therapies, reported a big loss for 2013 — but continued promising clincal trial results.
Esperion Therapeutics Inc. Tuesday announced positive results from a Phase 2a study of its drug candidate ETC-1002 when added to statin therapy in patients with high levels of low density lipoprotein cholesterol, the so-called bad cholesterol, in their blood.
Esperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
The Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.